Join Growin Stock Community!
Beta
Back to ASND.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
net-income-chart

ASND Net Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Ascendis pharma a/s (ASND) 2026Q1 financial report shows net profit of 629.34M EUR, with a YoY growth rate of 765.08%, a substantial increase, reflecting the company has entered a high growth phase, possibly benefiting from strong product sales or effective strategies. It is recommended to also monitor cash flow, revenue, and expense structure, and compare with peers. With Growin AI Value Analysis, the company is currently in a steady upward, high-growth stage, supported by strong fundamentals and ongoing momentum.